From anecdote to targeted therapy: The curious case of thalidomide in multiple myeloma

Jonathan D. Licht; Jake Shortt; Ricky Johnstone

doi:10.1016/j.ccr.2013.12.019

From anecdote to targeted therapy: The curious case of thalidomide in multiple myeloma

Jonathan D. Licht
, Jake Shortt
, Ricky Johnstone

Research output: Contribution to journal › Short survey › peer-review

35 Scopus citations

Abstract

Thalidomide and related drugs are key drugs for the treatment of multiple myeloma (MM). These agents bindto cereblon, a component of a ubiquitin ligase complex, altering the specificity of the complex to induce the ubiquitylation and degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for MMgrowth.

Original language	English
Pages (from-to)	9-11
Number of pages	3
Journal	Cancer Cell
Volume	25
Issue number	1
DOIs	https://doi.org/10.1016/j.ccr.2013.12.019
State	Published - 13 Jan 2014
Externally published	Yes

Access to Document

10.1016/j.ccr.2013.12.019

Cite this

@article{7fd0a3b9c9a04c1ba48e91d70a18950d,

title = "From anecdote to targeted therapy: The curious case of thalidomide in multiple myeloma",

abstract = "Thalidomide and related drugs are key drugs for the treatment of multiple myeloma (MM). These agents bindto cereblon, a component of a ubiquitin ligase complex, altering the specificity of the complex to induce the ubiquitylation and degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for MMgrowth.",

author = "Licht, \{Jonathan D.\} and Jake Shortt and Ricky Johnstone",

note = "Funding Information: This work was supported by an MMRF Program Grant in Epigenetics, NIH R01 CA123204, and a Leukemia and Lymphoma Society Specialized Center of Research Excellence Award.",

year = "2014",

month = jan,

day = "13",

doi = "10.1016/j.ccr.2013.12.019",

language = "English",

volume = "25",

pages = "9--11",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - From anecdote to targeted therapy

T2 - The curious case of thalidomide in multiple myeloma

AU - Licht, Jonathan D.

AU - Shortt, Jake

AU - Johnstone, Ricky

N1 - Funding Information: This work was supported by an MMRF Program Grant in Epigenetics, NIH R01 CA123204, and a Leukemia and Lymphoma Society Specialized Center of Research Excellence Award.

PY - 2014/1/13

Y1 - 2014/1/13

N2 - Thalidomide and related drugs are key drugs for the treatment of multiple myeloma (MM). These agents bindto cereblon, a component of a ubiquitin ligase complex, altering the specificity of the complex to induce the ubiquitylation and degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for MMgrowth.

AB - Thalidomide and related drugs are key drugs for the treatment of multiple myeloma (MM). These agents bindto cereblon, a component of a ubiquitin ligase complex, altering the specificity of the complex to induce the ubiquitylation and degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for MMgrowth.

UR - https://www.scopus.com/pages/publications/84892412407

U2 - 10.1016/j.ccr.2013.12.019

DO - 10.1016/j.ccr.2013.12.019

M3 - Short survey

AN - SCOPUS:84892412407

SN - 1535-6108

VL - 25

SP - 9

EP - 11

JO - Cancer Cell

JF - Cancer Cell

IS - 1

ER -

From anecdote to targeted therapy: The curious case of thalidomide in multiple myeloma

Abstract

Access to Document

Fingerprint

Cite this